Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Posted by Cynthia Vaughn on Feb 6th, 2025

Stock analysts at StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Up 2.7 %

NASDAQ:BCLI opened at $1.89 on Thursday. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89. The business’s 50-day moving average price is $1.98 and its two-hundred day moving average price is $2.82. The firm has a market capitalization of $10.78 million, a price-to-earnings ratio of -0.39 and a beta of 0.26.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.